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Tuberculosis treatment success among rural and urban  
Ugandans living with HIV: a retrospective study
J. Musaazi,1 A. N. Kiragga,1 B. Castelnuovo,1 A. Kambugu,1 J. Bradley,2 A. M. Rehman2
A sub-Saharan African country with both high tu-berculosis (TB) incidence and human immuno-
deficiency virus (HIV) prevalence, Uganda is among 
the 20 countries with the highest TB-HIV burden 
worldwide.1 TB incidence in Uganda in 2014–2015 
was estimated to be 174 smear-positive cases per 
100 000 population per year;1 HIV prevalence in 15–49 
year olds was 7.4% in 2012–2013.2 TB treatment suc-
cess rates have greatly improved in Uganda, from 44% 
in 1995 to 75% in 2014, approaching the 2015 World 
Health Organization (WHO) target of 85%.1
However, treatment success among TB patients 
living with HIV (PLHIV) are marginally lower than 
in their HIV-negative counterparts, both in Uganda 
(73% vs. 77%)1 and globally (73% vs. 88% in 2014).1 
Low TB treatment success among PLHIV has been 
documented in various studies conducted in Af-
rica.3,4 Rural health care settings report lower treat-
ment success than national rates,3–6 although the in-
troduction of the DOTS strategy may have improved 
rates.7
A qualitative evaluation identified health system 
barriers to TB treatment outcomes such as stock-outs 
of drugs and laboratory supplies, low motivation and 
poor co-ordination of services, as well as contextual 
barriers such as the cost of seeking treatment.8 Previ-
ous studies in Uganda showed that late presentation, 
patients lost to follow-up from treatment and inade-
quate treatment monitoring were associated with neg-
ative outcomes.9,10 
In the present study, we aimed to use data from 
routinely collected government facilities to identify 
factors that limit treatment success in Ugandan urban 
and rural settings among the vulnerable population of 
PLHIV.
METHODS
Study design, setting and population
A retrospective cross-sectional study of Uganda National 
Tuberculosis and Leprosy Programme (NTLP) routine 
data was conducted in 26 government health facilities 
in Kampala and western Uganda. The Ugandan health 
system is structured into five health facility levels, rang-
ing from village health team (HC-I) to specialised ser-
vices at the national referral hospital. TB treatment and 
diagnosis is available from HC-III facilities upwards, and 
most TB-HIV integrated care is available from HC-IV fa-
cilities upwards. Facilities (HC-III and upwards) were 
randomly sampled from rural and urban sites supported 
by the Infectious Diseases Institute (IDI), Kampala, 
Uganda. Six of eight urban Kampala City Council Au-
thority (KCCA) clinics were selected. Twenty rural facili-
ties from Western Uganda were selected from 44 avail-
able (Appendix Tables A.1 and A.2). Eligible participants 
were new pulmonary TB cases, PLHIV, aged 14 years, 
who initiated anti-tuberculosis treatment in 2014. Par-
ticipants were ineligible if they had multidrug-resistant 
TB (MDR-TB) or extensively drug-resistant TB (XDR-TB), 
or if their records were missing date of birth, age, TB di-
agnosis, TB regimen or date of treatment initiation. 
During the target period, the Uganda guidelines criteria 
for antiretroviral therapy (ART) were PLHIV with a CD4 
count of <350 cells/μl regardless of WHO stage, or all 
PLHIV diagnosed with TB.11,12 A rural setting was de-
fined as an area outside a city or big commercial town, 
while an urban setting was defined as a city or big com-
mercial town.
Anti-tuberculosis treatment
All clinics enrolled in the study followed the Uganda 
NTLP guidelines13 for TB diagnosis and treatment. 
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Setting: Government health centres and hospitals (six 
urban and 20 rural) providing tuberculosis (TB) treatment 
for people living with the human immunodeficiency virus 
(PLHIV) in central and western Uganda.
Objective: To identify and quantify modifiable factors 
that limit TB treatment success among PLHIV in rural 
Uganda.
Design: A retrospective cross-sectional review of routine 
Uganda National Tuberculosis and Leprosy Programme 
clinic registers and patient files of HIV-positive patients 
who received anti-tuberculosis treatment in 2014.
Results: Of 191 rural patients, 66.7% achieved treat-
ment success compared to 81.1% of 213 urban patients. 
Adjusted analysis revealed higher average treatment suc-
cess in urban patients than in rural patients (OR 3.95, 
95%CI 2.70–5.78, P < 0.01, generalised estimating equa-
tion model). Loss to follow-up was higher and follow-up 
sputum smear results were less frequently recorded in TB 
clinic registers among rural patients. Patients receiving 
treatment at higher-level facilities in rural settings had 
greater odds of treatment success, while patients receiv-
ing treatment at facilities where drug stock-outs had oc-
curred had lower odds of treatment success.
Conclusion: Lower reported treatment success in rural 
settings is mainly attributed to clinic-centred factors such 
as treatment monitoring procedures. We recommend 
strengthening treatment monitoring and delivery.
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New pulmonary TB patients were given first-line anti-tuberculosis 
treatment comprising a 2-month intensive phase of rifampicin 
(R), isoniazid (H), pyrazinamide (Z) and ethambutol (E) (2RHZE) 
and either a 6-month continuation phase comprising ethambutol 
(E) and isoniazid (H) (as combination: 6EH), or 4 months of ri-
fampicin (R) and isoniazid (H) (4RH). The 4RH regimen was stan-
dard care for people aged 15 years, and was used during drug 
stock-outs in some clinics.
Participants and data collection
Records were extracted between December 2015 and January 
2016. To attain a targeted sample size of 396 cases (198 cases each 
from rural and urban areas), we required at least 33 cases per 
clinic. To allow for missing data, we targeted 40 cases and there-
fore included all eligible cases in facilities with 40 cases, while 
in those with >40 cases, systematic sampling with probability pro-
portional to size was used.
Participants’ TB and HIV data were obtained from registers, 
HIV care cards in patient files and ART registers. Patients’ HIV 
care identification clinic numbers (IDCNO) were used to 
match TB and HIV data, but when these were missing from TB 
registers, demographic characteristics were used for matching. 
If a patient’s file could not be traced, the next eligible patient 
in the register was considered. Clinic-level data on drug stock-
outs, staffing, geographic location, possession of microscopy 
and other clinic activities such as patient tracing were ob-
tained from review of annual reports and from staff at the TB 
clinic.
Data were double-entered into Epi Info™ 7 statistical software 
(Centers for Disease Control and Prevention, Atlanta, GA, USA), 
verified for consistency, and transferred to Stata 13.1 software 
(Stata LP, College Station, TX, USA) for analysis.
Statistical analysis and outcomes
With 80% power, a significance of 5% and a sampling ratio of 1:1 
in urban:rural clinics, 322 patients were required to detect a dif-
ference in treatment success, from 71%14 in urban clinics to 56% 
in rural clinics, based on an estimated difference of 15% between 
success rates. To allow for clustering effects, the sample size was 
inflated by 20%, making a target sample size of 396.
The primary outcome was the proportion of participants with 
treatment success (defined as cure or treatment completed) com-
paring rural and urban participants. Secondary outcomes were 
standard end of treatment measures, defined according to the 
Uganda NTLP and the WHO1,13 (Appendix Table A.3). Logistic 
generalised estimating equations (GEE) models with clinics as 
clusters, odds ratios (ORs) and 95% confidence intervals (CIs) 
were used to examine measured potential predictors of TB treat-
ment success. Factors examined in the analysis included patient 
characteristics at TB treatment start (age, sex, CD4 cell count, 
body mass index [BMI], ART treatment history, living in a differ-
ent subcounty from the clinic, and nature of TB diagnosis: bacte-
riologically confirmed or clinically diagnosed), status during TB 
treatment (timing of ART initiation among the ART-naïve, comor-
bidities that interfere with patient adherence, such as stomach ul-
cer and malaria, missed TB doses, missed clinic appointments, re-
ceived 4 weeks’ supply of anti-tuberculosis drugs for the intensive 
phase) and clinic factors (health facility level, TB drug stock-outs, 
number of staff at TB clinic by qualification, patient load at TB 
clinic). All analyses used inverse probability weighting to account 
for unequal sampling probability of participants at each clinic. 
Sex, age and being on ART at the start of anti-tuberculosis treat-
ment were a priori factors included in the adjusted model. All 
variables with P values <0.3 were then added to the adjusted 
model and removed if P > 0.3 in the adjusted model. All remain-
ing variables were tested again one by one, and included if P < 0.3 
in the adjusted model.
Ethical considerations
The ethics committees of the London School of Hygiene & Tropi-
cal Medicine, London, UK (LSHTM reference 9761), The AIDS 
Support Organization (TASO), Kampala, Uganda (number: TASO-
REC/062/15-UG-REC-009) and the Uganda National Council for 
Science and Technology, Kampala, Uganda (UNCST number: HS 
1965) granted ethical approval for the study. Due to the retrospec-
tive study design and strict anonymity of participants, the need 
for patient consent was waived. However, written consent was ob-
tained from TB clinic staff who provided clinic-level data.
RESULTS
Of 2810 individuals initiated on anti-tuberculosis treatment 
during the study period in 26 clinics studied, 871 met the inclu-
sion criteria: TB and HIV data were obtained for 191 rural and 213 
urban participants (Figure 1). The majority were male (61.1%), 
and had been prescribed 2RHZE/6EH (92.0%); the mean age was 
35 years (standard deviation 10) and 40.7% were on ART at the 
start of anti-tuberculosis treatment (Table 1). At 2 months, 235 
(51.2%) participants had follow-up sputum smear results, 183 
(42.4%) at 5 months and 174 (40.9%) at 8 months (Figure 2). 
Treatment was successful for 81.1% of 213 participants in urban 
facilities and 66.7% of 191 participants in rural facilities (Table 2). 
Urban patients were more likely to have achieved treatment suc-
cess than rural patients (adjusted OR [aOR] 3.95, 95%CI 2.70–
5.78, P < 0.01; Table 3). There was no evidence of an independent 
FIGURE 1 Numbers screened and analysed. TB = tuberculosis; HIV 
= human immunodeficiency virus.
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association of sex, age and ART status with treatment success (Ta-
ble 3). Analysis of secondary outcomes revealed that 41.4% were 
cured (17.0% in rural, 65.7% in urban areas), 32.5% completed 
treatment (49.7% in rural, 15.4% in urban areas), 1% had failed 
and 8.1% had died, whereas 6.9% of patient outcomes could not 
be evaluated and 10.1% of the participants had become lost to 
follow-up (LTFU), with rural clinics having a higher proportion of 
cases LTFU than urban clinics (16.6% vs. 3.5%; Table 2).
The median number of participants per clinic was nine (inter-
quartile range [IQR] 4–13) in rural and 34 (IQR 32–39) in urban 
TABLE 1 Sociodemographic, clinical and facility characteristics by urban or rural location*
All
(n = 404)
%
Rural
(n = 191, 47%)
%
Urban
(n = 213, 53%)
% P value†
Characteristics at start of anti-tuberculosis treatment
 Male sex 61.1 60.9 61.4 0.929
 Age, years, mean ± SD 34.5 ± 10 34.8 ± 13 34.3 ± 6 0.607
  14–34 54.7 53.1 56.3 0.413
  35 45.3 46.9 43.7
 On ART‡ 40.7 49.3 32.2 0.007
 CD4 count, cells/μl, median [IQR]§ 188 [62–422] 140 [58–367] 256 [75–487] 0.844
  <200 51.3 57.1 42.5 0.345
  200 48.7 42.9 57.5
 BMI < 18.5 kg/m2§ 41.7 38.4 46.1 0.412
 Lived in subcounty different from that of clinic§ 56.4 61.5 51.6 0.380
 TB bacteriologically confirmed 72.9 67.2 78.7 0.243
 Health facility level
  HC-III 33.6 17.0 50.2 0.469
  HC-IV 36.5 43.7 29.4
  Hospital 29.9 39.3 20.4
Characteristics of anti-tuberculosis treatment
 TB regimen
  2RHZE/6EH 92.0 90.4 93.5 0.623
  2RHZE/4RH 8.0 9.6 6.5
 TB prescription pattern
  Prescribed 4 weeks’ supply for the intensive phase 18.0 27.5 8.6 0.074
  Prescribed 8 weeks’ supply for the continuation phase§ 13.9 6.3 20.9 0.280
  Was not prescribed enough medications at least once 5.0 3.7 6.2 0.533
 Appointment attendance
  Number attended, median [IQR] 9 [6–10] 8 [4–10] 9 [7–10] <0.001
  Attended at least 7 days late (in the intensive phase) or  
14 days late (in the continuation phase)
43.8 53.3 34.4 0.027
  Missed a dose (scheduled appointments) 31.4 39.1 23.7 0.062
 Time of ART initiation among ART-naïve patients at  
start of TB treatment§
  <2 weeks 23.9 15.5 29.6 0.010
  2–8 weeks 54.5 48.6 58.5
  >8 weeks 21.6 36.0 11.9
 Experienced comorbidity¶ 15.8 15.8 15.8 0.992
Characteristics of clinics (n = 26) (n = 20) (n = 6)
 Health facility level
  HC-III 46.2 40.0 66.7 0.479
  HC-IV 38.5 45.0 16.7
  Hospital 15.4 15.0 16.7
 Stock-out of anti-tuberculosis drugs in 2014 57.7 50.0 83.3 0.197
 TB clinic had a counsellor 50.0 50.0 50.0 1.000
* All estimates and P values are adjusted for sampling weights.
† P values compare rural and urban estimates.
‡ Of patients on ART, 96% were on an efavirenz-based regimen; 5% switched ART regimens during the course of anti-tuberculosis treatment.
§ Missing values for CD4 cell count: overall (n = 296, 73%), urban (n = 171, 80%), rural (n = 125, 65%); for BMI: overall (n = 289, 72%), urban (n = 152, 71%), rural (n = 137, 
72%); lived in different subcounty to clinic: overall (n = 7, 2%), urban (n = 0, 0%), rural (n = 7, 4%); prescribed 8 weeks’ supply during the continuation phase: overall (n = 55, 
14%), urban, (n = 18, 8%), rural (n = 37, 19%).
¶ Any of the following recorded on TB or HIV clinic cards during TB treatment period: gastroenteritis, diarrhoea, anaemia, vomiting, malaria, peripheral neuropathy, hyperten-
sion documented on record, gastrointestinal disease, Kaposi’s sarcoma, cryptococcal meningitis, stomach ulcer.
SD = standard deviation; ART = antiretroviral therapy; IQR = interquartile range; BMI = body mass index; TB = tuberculosis; HC = health centre; R = rifampicin; H = isoniazid; Z 
= pyrazinamide; E = ethambutol; HIV = human immunodeficiency virus.
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facilities. Sputum smear results in TB registers were significantly 
more likely to be recorded in urban than in rural facilities at all 
times (P < 0.001), and did not depend on the level of health facil-
ity (P = 0.480). Clinic-level treatment success ranged from 72% to 
91% in urban and 0% to 100% in rural facilities. The two clinics 
with 0% success had less than five patients; one had no counsel-
lor and one reported TB drug stock-outs during the period stud-
ied. Having a TB drug stock-out was associated with lower treat-
ment success (aOR 0.38, 95%CI 0.24–0.60, P < 0.01), while having 
a counsellor in the clinic was associated with on average 55% 
higher odds of treatment success (aOR 1.55, 95%CI 1.05–2.28, P = 
0.03; Table 3). Treatment success increased with health facility 
level in rural areas: 49.1% at HC-III, 64.8% at HC-IV and 76.4% at 
hospital level (P value for interaction <0.01: Appendix Table A.4). 
For urban clinics, treatment success was highest in hospitals 
(90.9%) and lowest in HC-IV facilities (72.4%). TB-HIV integrated 
services were being implemented in five of the six urban health 
facilities and nine of the 20 rural health facilities during the study 
period.
DISCUSSION
TB treatment success rates among PLHIV vary widely among 
sub-Saharan African countries,15–21 and our study findings fit 
within this range. Studies that reported better treatment success 
rates than our study had more well-organised community-based 
DOTS programmes and better patient tracing7,17,22–24 than most 
rural clinics in our study. The higher proportion of patients re-
ported as LTFU by rural clinics was likely related to patient char-
acteristics: such patients lived further from health facilities, pre-
sented later for treatment, were more likely to be malnourished, 
and had lower CD4 cell counts at diagnosis than their urban 
counterparts and received less treatment monitoring than urban 
patients, consistent with other studies in Uganda and elsewhere 
in sub-Saharan Africa.3,5,8,21,25
Treatment monitoring was key to the improved treatment suc-
cess in urban clinics. The availability of follow-up sputum smear 
results was less common for rural patients, despite the presence of 
microscopes in all facilities. Facilities reported lack of laboratory 
supplies such as reagents, which limited the performance of spu-
tum testing. In addition, data management was poor in most ru-
ral clinics, resulting in missing sputum results and treatment out-
comes in TB registers even when the tests were performed. Efforts 
were made to obtain missing outcome data, but we were limited 
by what was recorded in the TB registers. A comparable rural 
Ugandan study found that of 264 511 patient encounters, 1.8% 
had sputum smear microscopy prescribed, of which 60% under-
went a complete evaluation.26 Fewer rural health facilities had TB-
HIV integrated care than urban facilities. Rural clinics may have 
tailored TB appointments to coincide with HIV clinic appoint-
ments for HIV patients on anti-tuberculosis treatment, specifically 
due to the longer distances to the health facility. This could have 
contributed to poor adherence to anti-tuberculosis treatment 
among rural patients due to a lack of adequate monitoring.
Stock-outs in the facilities studied were most common for the 
drug combination administered during the intensive phase 
(RHZE), and lasted on average for 2 months (maximum 8 
months). As in other studies,27 causes of reported stock-outs were 
delayed supply of drugs from national medical stores and poor 
forecast of requirements of drugs by the clinics. Solutions re-
ported were borrowing from nearby clinics or issuing alternative 
drugs. Drug stock-outs of antiretroviral or anti-tuberculosis drugs 
were also reported in 25% of 2454 South African health facilities 
studied in 2014.27 Adequate funding and commitment among the 
stakeholders responsible for procurement, custody and issuing of 
drugs may reduce stock-outs of essential drugs in public health 
facilities in sub-Saharan Africa.27
Furthermore, the presence of counsellors in the team of TB 
clinic staff is undoubtedly related to better-resourced—and proba-
FIGURE 2 Percentage of patients with sputum smear results re-
corded in TB registers: all patients (n = 404), rural patients, (n = 191), 
urban patients (n = 213). Comparison of urban and rural percentage 
at 2 months P value = 0.003, at 5 months P < 0.001 and at 8 months 
P < 0.001. TB = tuberculosis.
TABLE 2 Percentage of patients with anti-tuberculosis treatment outcomes by urban or rural location
Outcome
All
%
Rural
%
Urban
% P value*
Smear-negative at 2 months 88.5 (n = 208) 85.9 (n = 67) 89.8 (n = 141) 0.376
Smear-negative at 5 months 98.4 (n = 180) 96.0 (n = 48) 99.3 (n = 132) 0.123
Smear-negative at 8 months 98.3 (n = 171) 100.0 (n = 32) 97.9 (n = 139) 0.407
All (n = 404) Rural (n = 191) Urban (n = 211)
Cured 41.4 17.0 65.7 <0.001
Treatment completed 32.5 49.7 15.4
Treatment failed 1.0 0.7 1.3
Died 8.1 7.6 8.7
Not evaluated† 6.9 8.4 5.3
Lost to follow-up 10.1 16.6 3.5
Treatment success 73.9 66.7 81.1 0.030
* χ2 comparison of rural vs. urban locations adjusted for sampling weights.
† Includes results not documented and transferred out.
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TABLE 3 Sociodemographic, clinical and facility characteristics associated with TB treatment success by urban or rural location
n
Treatment  
success  
%* OR (95%CI)* P value* aOR (95%CI)* P value*
Characteristics at start of  
anti-tuberculosis treatment
 Clinic location
  Rural 191 66.7 1 1
  Urban 213 81.1 2.20 (1.15–4.21) 0.02 3.95 (2.70–5.78) <0.01
 Sex
  Male 255 70.6 1 1
  Female 149 79.1 1.53 (0.79–2.97) 0.20 1.58 (0.77–3.24) 0.21
 Age, years
  14–34 218 71.5 1 1
  35 186 76.8 1.28 (0.84–1.96) 0.24 1.28 (0.84–1.97) 0.25
 On ART
  No 241 75.5 1 1
  Yes 163 71.6 0.91 (0.64–1.29) 0.59 0.99 (0.61–1.61) 0.98
 Lived in subcounty different from  
that of clinic†
  No 189 72.3 1
  Yes 208 75.7 1.28 (0.86–1.91) 0.26 — —
 TB bacteriologically confirmed
  No 99 78.4 1 1
  Yes 305 72.2 0.70 (0.40–1.21) 0.20 0.64 (0.32–1.28) 0.20
 Health facility level
  HC-III 191 73.9 1 1
  HC-IV 124 67.9 0.96 (0.41–2.24) 0.12 1.15 (0.74–1.79) <0.01
  Hospital 89 81.4 1.92 (0.86–4.29) 3.48 (2.20–5.52)
Characteristics of anti-tuberculosis  
treatment
 TB regimen
  2RHZE/6EH 384 73.3 1
  2RHZE/4RH 20 80.7 1.52 (0.35,6.58) 0.56 — —
 TB prescription pattern
  Intensive phase
   Prescribed 2 weeks’ supply 348 75.9 1
   Prescribed 4 weeks’ supply 56 64.7 0.59 (0.28–1.23) 0.16 — —
  Continuation phase†
   Prescribed 4 weeks’ supply 314 81.4 1
   Prescribed 8 weeks’ supply 35 93.2 3.09 (1.70–5.64) <0.01 — —
 Insufficient drugs prescribed at least once
  No 380 73.7 1
  Yes 24 78.0 1.22 (0.60–2.49) 0.59 — —
 Appointment attendance, prompt 233 73.6 1
 Late at least once 171 74.3 1.11 (0.69–1.79) 0.67 — —
 Missed a dose ever
  No 285 74.0 1
  Yes 119 73.8 1.08 (0.59–2.00) 0.80 — —
 Experienced comorbidity‡
  No 328 74.5 1
  Yes 76 70.6 0.79 (0.50–1.24) 0.31 — —
 Stock-out of anti-tuberculosis drugs  
during 2014
  No 106 76.4 1 1
  Yes 298 73.2 0.78 (0.31–1.98) 0.61 0.38 (0.24–0.60) <0.01
 TB clinic had a counsellor
  No 189 73.8 1 1
  Yes 215 74.0 1.02 (0.49–2.13) 0.96 1.55 (1.05–2.28) 0.03
* Estimates and P values adjust for clinic as a cluster and use sampling weights.
† Missing values for ‘lived in different subcounty from that of clinic’: overall (n = 7, 2%), urban (n = 0, 0%), rural (n = 7, 4%); prescribed 8 weeks’ supply during the continua-
tion phase: overall (n = 55, 14%), urban (n = 18, 8%), rural (n = 37, 19%).
‡ Any of the following recorded on TB or HIV clinic cards during TB treatment period: gastroenteritis, diarrhoea, anaemia, vomiting, malaria, peripheral neuropathy, hyperten-
sion documented on record, gastrointestinal disease, Kaposi’s sarcoma, cryptococcal meningitis, stomach ulcer.
TB = tuberculosis; OR = odds ratio; CI = confidence interval; aOR = adjusted OR; ART = antiretroviral therapy; HC = health centre; R = rifampicin; H = isoniazid; Z = pyrazin-
amide; E = ethambutol; HIV = human immunodeficiency virus.
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bly higher level—clinics. Counselling services have been previ-
ously shown to improve treatment success.9 The higher treatment 
success rates in urban sites may be attributable to programmes be-
ing implemented in KCCA clinics (TB Care 128 and TRACK-TB 
[project ongoing until 2017]), but not in rural clinics. These pro-
grammes aimed to improve the quality of TB treatment care, ad-
herence, treatment outcomes, data quality/documentation and 
drug management. The reports from such programmes have 
shown significant improvements in documentation in patients’ 
medical records as a result of TB staff training and support super-
vision.28 Such programmes should be extended to rural settings to 
achieve nationwide improvements in treatment success. The in-
terrelationship between patient-level and clinic-level factors high-
lights the obstacles to improving treatment success.29,30
Both a strength and a weakness of this study was that it used 
data routinely collected from public health facilities at primary 
health care level. The inclusion of public health facilities from 
outlying rural areas provided good representation of routine TB 
care in Uganda, although routine hospital data may suffer from 
incomplete recording, resulting in missing data, including out-
come data. We correctly analysed the data using sampling weights 
to account for multiple site sampling. Because we restricted data 
collection to clinics supported by IDI and to patients with linked 
TB-HIV data, this may have limited the generalisability of our 
findings to clinics that were not providing these services. This 
may have led to an estimation of greater treatment success than 
would be expected in non-IDI clinics. However, this should not 
affect the urban-rural comparison, as this restriction was imposed 
in both areas. Furthermore, many proxy variables had to be used, 
for example distance to clinic (not collected in data sources used), 
which was approximated by residence in another subcounty. 
Linkage of TB and HIV health records was less likely in rural set-
tings, among males and among LTFU patients, which may have 
overestimated treatment success due to the exclusion of high 
numbers of LTFU patients that would otherwise be categorised as 
unfavourable outcomes.
CONCLUSION
The lower reported treatment success rates in rural clinics are 
likely a combination of patient-centred factors, such as late pre-
sentation and distance to clinic, and clinic-centred factors, such 
as staff unavailability for treatment monitoring and follow-up. 
We recommend the reinforcement of community-based TB treat-
ment, especially in rural settings, active tracing of patients who 
miss appointments and increased staff training on treatment 
monitoring and delivery, and good data management.
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APPENDIX
TABLE A.1 List of sampled health facilities
District Name of health facility Health facility level
Sample
n
New PTB-HIV
patients in 2014*
n
Urban sites 213 436
 Kampala City Naguru Hospital Hospital 33 89
Kisenyi Health Center IV 29 128
Kiswa Health Center III 44 56
Komamboga Health Center III 39 51
Kisugu Health Center III 35 49
Kitebi Health Center III 33 63
Rural sites 191 435
 Kiboga District Kiboga Hospital Hospital 20 48
Bukomero Health Center IV 24 30
Lwamata Health Center III 6 9
 Kyankwanzi District Ntwetwe Health Center IV 8 14
Butemba Health Center III 13 20
Kyankwanzi Health Center III 3 4
 Kibaale District Kagadi Hospital Hospital 24 104
Kakumiro Health Center IV 13 38
Kibaale Health Center IV 6 14
 Hoima District Kikuube Health Center IV 11 12
Kigorobya Health Center IV 14 25
Kyangwali Health Center III 2 12
 Masindi District Bwijanga Health Center IV 11 17
 Buliisa District Buliisa Health Center IV 6 15
Biiso Health Center III 4 8
 Kiryandongo District Kiryandongo Hospital Hospital 12 19
Mutunda Health Center III 1 2
Diima Health Center III 2 4
Panyandoli Health Center III 9 15
Kakindo Health Center IV 2 25
 Total 404 871
* Aged 14 years.
PTB = pulmonary tuberculosis; HIV = human immunodeficiency virus.
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TABLE A.2 Districts in Uganda and accredited government health 
facilities for HIV care where the Infectious Diseases Institute 
(Kampala, Uganda) offered support up to May 2015
Districts Health facilities
Kampala Naguru Hospital*
Kisenyi HC-IV*
Kiswa HC-III*
Komamboga HC-III*
Kisugu HC-III*
Kitebi HC-III*
Kawempe Hospital
Kirudu Hospital
Kiboga Kiboga Hospital*
Bukomero HC-IV*
Lwamata HC-III*
Katwe HC-III
Muwanga HC-III
Kyankwanzi Ntwetwe HC-IV*
Butemba HC-III*
Kyankwanzi HC-III*
Kikonda HC-III
Kiyuni HC-III
St Balikudembe HC-III
Kibaale Kagadi Hospital*
Kakindo HC-IV*
Kibaale HC-IV*
Kakumiro HC-IV*
Kisiita HC-III
Kyaterekera HC-III
Nkooko HC-III
Nyamarwa HC-III
Kinyarugonjo HC-III
Kiryandongo Kiryandongo Hospital*
Kigumba HC-III
Panyadoli HC-III*
Mutunda HC-III*
Diima HC-III*
Masindi Port HC-III
Buliisa Buliisa HC-IV*
Biiso HC-III*
Butiaba HC-II
Avogera HC-II
Masindi Bwijanga HC-IV*
Pakanyi HC-III
Nyakitibwa HC-III
Kyatiri HC-III
Hoima Kikuube HC-IV*
Kigorobya HC-IV*
Kyangwali HC-III*
Kabwoya HC-III
Dwooli HC-III
Kabaale HC-III
Butema HC-III
Buseruka HC-III
Rwenyawawa HC-III
Buhanika HC-III
Karongo HC-II
Nsozi HC-III
Buhimba HC-III
Mparangasi HC-III
Mukabara HC-III
TABLE A.2 (continued)
Districts Health facilities
Hoima Buraru HC-III
Bugambe HC-III
Bujugu HC-III
Bujumbura HC-III
Muhwiju HC-III
Bujalya HC-III
Kaseeta HC-III
* Included in this study.
HIV = human immunodeficiency virus; HC = health centre.
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Reference
1 World Health Organization. Definitions and reporting framework for tuber-
culosis: 2013 revision. WHO/HTM/TB/2013.2. Geneva, Switzerland: WHO, 
2014.
TABLE A.4 TB treatment success across health facility level stratified by rural/urban
Health facility level
Rural* Urban‡
Patients with  
treatment success
n (%) aOR (95%CI)†
Patients with  
treatment success
n (%) aOR (95%CI)†
HC-III 40 (49.1) 1 151 (82.2) 1
HC-IV 95 (64.8) 2.44 (0.95–6.27) 29 (72.4) 0.84 (0.62–1.13)
Hospital 56 (76.4) 6.45 (2.90–14.36) 33 (90.9) 2.50 (1.75–3.55)
 Total 191 (66.7) 213 (81.1)
P value — <0.001 — 0.109
* Includes 8 HC-IIIs, 9 HC-IVs and 3 hospitals.
† Adjusted for participants’ baseline characteristics: sex, age, type of TB diagnosis, bacteriological or clinical.
‡ Includes 4 HC-IIIs, 1 HC-IV, 1 hospital.
TB = tuberculosis; aOR = adjusted odds ratio; CI = confidence interval; HC = health centre.
TABLE A.3 Definition of key terms taken from WHO guidelines1
Term Definition
Bacteriologically confirmed TB case Defined as a patient with a biological specimen that is positive on smear microscopy, culture or WRD, such as 
Xpert® MTB/RIF
Clinically diagnosed TB case Patient who does not fulfil the criteria for bacteriological confirmation but has been diagnosed with active TB 
by a clinician or any other medical practitioner who has prescribed the patient a full course of anti-
tuberculosis treatment. This also includes X-ray abnormalities or suggestive histology and EPTB cases without 
laboratory confirmation
PTB Refers to any bacteriologically confirmed or clinically diagnosed case of TB involving the lung parenchyma or 
the tracheobronchial tree. This also includes miliary TB. Patients with both PTB and EPTB are classified as PTB
EPTB Refers to any bacteriologically confirmed or clinically diagnosed TB case involving organs other than the lungs, 
such as pleura, lymph nodes, abdomen, genitourinary tract, skin, joints and bones, meninges
TB relapse Patient who has previously been treated for TB, was declared cured or treatment completed at the end of their 
most recent course of treatment, and is now diagnosed with a recurrent episode of TB (either a true relapse 
or a new episode of TB caused by re-infection)
Treatment after failure Patient who was previously treated for TB and whose treatment failed at the end of their most recent course of 
treatment
HIV-positive TB patient Refers to a bacteriologically confirmed or clinically diagnosed TB case who is HIV-positive at the time of TB 
diagnosis or any other evidence of enrolment into HIV care, such as enrolment into pre-ART register or in 
ART register once ART has been started
Cure A PTB patient with bacteriologically confirmed TB at the beginning of treatment, who is smear- or culture-
negative in the last month of treatment and on at least one previous occasion
Treatment completed A TB patient who completed treatment without evidence of failure BUT with no record to show that sputum 
smear or culture results in the last month of treatment and on at least one previous occasion were negative, 
either because tests were not performed or results were unavailable
Treatment failed A patient whose sputum smear or culture is positive at month 5 or later during treatment
Died A TB patient who dies for any reason before starting or during treatment
Lost to follow-up A patient who did not start treatment or whose treatment was interrupted for 2 consecutive months
Not evaluated A TB patient for whom no treatment outcome is assigned. This includes cases transferred out to other 
treatment units as well as TB patients whose treatment outcome is unknown to the reporting unit
Treatment success Sum of cured and treatment completed
WHO = World Health Organization; TB = tuberculosis; WRD = WHO-endorsed rapid diagnostic device; PTB = pulmonary TB; EPTB = extra-pulmonary TB; HIV = human immu-
nodeficiency virus; ART = antiretroviral therapy.
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Contexte  :  L’étude a été réalisée dans des centres de santé et des 
hôpitaux publics, six urbains et 20 ruraux, fournissant un traitement 
de la tuberculose (TB) aux personnes vivant avec le VIH (PVVIH) dans 
le centre et l’ouest de l’Ouganda.
Objectif  :  Identifier et quantifier les facteurs modifiables qui limitent le 
succès du traitement de la TB parmi les PVVIH dans l’Ouganda rural.
Schéma  :  Une revue rétrospective transversale des registres cliniques 
et des dossiers de patients du Programme national tuberculose et 
lèpre d’Ouganda pour les patients VIH positifs qui ont reçu un 
traitement de TB en 2014.
Résultats  :  Parmi 191 patients ruraux, 66,7% ont eu un bon résultat 
de leur traitement, tandis que parmi 213 patients urbains, 81,1% ont 
eu un bon résultat. Une analyse ajustée a révélé un succès 
thérapeutique moyen plus élevé chez les patients urbains comparés 
aux patients ruraux (OR 3,95 ; IC95% 2,70–5,78 ; P < 0,01 ; modèle 
d’équation d’estimation généralisée). Les pertes de vue ont été plus 
élevées et les résultats de frottis de crachats de suivi ont été moins 
souvent enregistrés dans les registres des centres TB pour les patients 
ruraux. Les patients recevant un traitement dans des structures de 
plus haut niveau, toujours en zone rurale, avaient plus de chances 
d’avoir un succès thérapeutique. Les patients recevant leur traitement 
dans des structures où étaient survenues des ruptures de stock de 
médicaments avaient moins de chances de succès thérapeutique.
Conclusion  :  Les taux plus faibles de succès du traitement rapportés 
en zone rurale sont en majorité attribués à des facteurs liés aux 
centres de santé, comme les procédures de suivi du traitement. Nous 
recommandons le renforcement de la fourniture et du suivi du 
traitement.
Marco de referencia: El estudio se llevó a cabo en centros de salud y 
hospitales del sector público, seis en entornos urbanos y 20 en medio 
rural y consistió en suministrar el tratamiento antituberculoso a las 
personas positivas frente al virus de la inmunodeficiencia humana 
(VIH) en la región central y occidental de Uganda.
Objetivo: Determinar y cuantificar los factores modificables que 
limitan la eficacia del tratamiento antituberculoso en las personas 
positivas frente al VIH en las zonas rurales de Uganda.
Método: Fue este un estudio transversal retrospectivo de análisis de 
los registros corrientes y las historias clínicas de los pacientes positivos 
frente al VIH, en los consultorios del Programa Nacional contra la 
Tuberculosis y la Lepra de Uganda en el 2014.
Resultados: De los 191 pacientes de entornos rurales, el 66,7% 
logró un tratamiento eficaz y en los 213 pacientes en medio urbano 
esta proporción fue 81,1%. Un análisis ajustado reveló un promedio 
de éxito terapéutico más alto en los pacientes urbanos en 
comparación con los pacientes rurales (OR 3,95; IC95% de 2,70 a 
5,78; P < 0,01, según un modelo de ecuaciones de estimación 
generalizadas). En medio rural, se observó una mayor pérdida 
durante el seguimiento y se consignaban con menor frecuencia los 
resultados de las baciloscopias de seguimiento en los registros de 
tuberculosis de los consultorios. Los pacientes que recibían 
tratamiento en los establecimientos de nivel de atención más alto en 
medio rural tenían mayores posibilidades de éxito terapéutico. Los 
pacientes que recibían tratamiento en centros que presentaban 
desabastecimientos de medicamentos tuvieron menos probabilidades 
de lograr un tratamiento eficaz.
Conclusión: La menor proporción de éxito terapéutico notificada en 
los entornos rurales se debe en su mayor parte a factores que 
dependen del consultorio, como los procedimientos de supervisión 
del tratamiento. Se recomienda reforzar la supervisión y el suministro 
del tratamiento antituberculoso.
